Nurix Therapeutics Balance Sheet
NASDAQ: NRIXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics financial position
At the end of fiscal 2025, Nurix Therapeutics reported total assets of $688.1 million, up 2.8% from a year earlier against total liabilities of $149.4 million. Shareholders' equity stood at $538.7 million, or 78.3% of assets. The company held $247.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 7.02, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Nurix Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-11-30 | FY 20242024-11-30 | FY 20232023-11-30 | FY 20222022-11-30 | FY 20212021-11-30 | FY 20202020-11-30 | FY 20192019-11-30 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 246.96M | 110.00M | 54.63M | 64.47M | 80.51M | 119.36M | 34.82M |
| Short-Term Investments | — | — | — | 244.67M | 215.21M | 161.79M | 2.90M |
| Receivables | — | 0 | — | 0 | 6.00M | — | — |
| Total Current Assets | 606.82M | 619.39M | 295.50M | 318.45M | 311.12M | 298.43M | 39.35M |
| Property, Plant & Equipment | 22.49M | 17.76M | 16.81M | 17.16M | 11.34M | 6.67M | 3.87M |
| Long-Term Investments | — | — | — | 63.88M | 137.19M | 90.89M | 506.00K |
| Total Assets | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M | 396.34M | 44.05M |
| Accounts Payable | 11.21M | 11.48M | 6.40M | 5.06M | 6.65M | 3.41M | 1.60M |
| Total Current Liabilities | 86.47M | 95.85M | 86.96M | 70.66M | 66.26M | 44.54M | 16.14M |
| Total Liabilities | 149.39M | 142.35M | 155.10M | 113.06M | 134.47M | 106.07M | 53.57M |
| Shareholders' Equity | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M | 290.27M | -57.71M |
| Retained Earnings | -1.00B | -738.77M | -545.20M | -401.25M | -220.89M | -103.70M | -60.46M |
| Net Cash (Debt) | 246.96M | 110.00M | 54.63M | 309.14M | 295.72M | 281.15M | 37.72M |
| Shares Outstanding | 101.81M | 75.87M | 48.72M | 47.17M | 44.66M | 38.86M | 3.60M |
This table shows 7 annual periods of Nurix Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NRIX's reporting calendar. What is a balance sheet?